anti-CD272 [BTLA] (human), mAb (ANC6E9) (APC)
|Synonyms||BTLA; B- and T-lymphocyte Attenuator|
|Product Type||Monoclonal Antibody|
|Immunogen/Antigen||Recombinant soluble human CD272.|
|Formulation||50mM Sodium Phosphate pH 7.5, 500mM Potassium Chloride, 150mM NaCl, 15% Glycerol, 0.2% BSA, 0.04% NaN3 (as a preservative).|
|Isotype Negative Control|
|Other Product Data||
Click here for Original Manufacturer Product Datasheet
|Declaration||Manufactured by Ancell Corporation.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
Do not freeze.
Protect from light.
|Use/Stability||Stable for at least 1 year after receipt when stored at +4°C.|
|Product Specification Sheet|
Human CD272 (BTLA; B and T Lymphocyte Attenuator) is a member of the immunoglobulin superfamily and has sequence homology to PD-1 and CTLA-4. It is expressed on T and B lymphocytes and other hemopoetic lineages. Engagement of this molecule by its ligand CD270 (HVEM) can downregulate activated T and B cell responses. CD272 levels on antigen specific CD8+ T cells have been reported to decrease in viral specific, but not melanoma specific activated lines. Polymorphism of the CD272 molecule has been linked to rheumatoid arthritis.